PHP
CDTX

Parkman Healthcare Partners’s Cidara Therapeutics CDTX Stock Holding History

Parkman Healthcare Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,801
Closed -$154K – 104
2023
Q2 		$154K Sell
6,801
-23,199
-77% -$545K 0.03% 95
2023
Q1 		$762K Buy
+30,000
New +$851K 0.17% 74

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Parkman Healthcare Partners's CDTX Position: Q3 2023 in Review

Parkman Healthcare Partners sold out of Cidara Therapeutics (CDTX) in Q3 2023, closing a stake of 6,801 shares — an estimated $154K sold.

Parkman Healthcare Partners first reported a position in CDTX in Q1 2023 and held it in 2 quarters. The position peaked at $762K in Q1 2023. 52 funds tracked by Wall St. Rank hold CDTX as of Q3 2023.

  • Parkman Healthcare Partners reported no remaining Cidara Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 6,801 Cidara Therapeutics shares in Q3 2023, an estimated $154K.
  • Parkman Healthcare Partners first reported a position in Cidara Therapeutics in Q1 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Cidara Therapeutics position peaked at $762K in Q1 2023.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2023.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.